Literature DB >> 7648646

Nifedipine and mortality. Grave defects in the dossier.

L H Opie, F H Messerli.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7648646     DOI: 10.1161/01.cir.92.5.1068

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  23 in total

1.  Are calcium antagonists safe in hypertension?

Authors:  G Y Lip; D G Beevers
Journal:  Postgrad Med J       Date:  1996-04       Impact factor: 2.401

2.  The prevention of cardiovascular events. A new challenge for calcium channel blockers. Introduction.

Authors:  K I Lie
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 3.  How do calcium channel blockers prevent cardiovascular events. Are they all alike?

Authors:  M G Bogaert
Journal:  Drugs       Date:  1996       Impact factor: 9.546

4.  1,4-Dihydropyridines versus beta-blockers for hypertension: are either safe for the heart?

Authors:  F H Leenen
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

5.  Controversies concerning calcium antagonists.

Authors:  P R Lichtlen
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

6.  Calcium channel blocker debate: true lies?

Authors:  J Leor; A Battler
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

Review 7.  Bioequivalence of controlled-release calcium antagonists.

Authors:  R Schall; F R Müller; F O Müller; H G Luus
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

Review 8.  Calcium channel antagonists should be among the first-line drugs in the management of cardiovascular disease.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

Review 9.  Calcium antagonists in the elderly. A risk-benefit analysis.

Authors:  J B Schwartz
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

Review 10.  Has the role of calcium channel blockers in treating hypertension finally been defined?

Authors:  George S Chrysant; Steven G Chrysant
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.